Lineage Cell Therapeutics grants 694,424 RSUs tied to Roche collaboration milestones

Lineage Cell Therapeutics, Inc.

RSUs awarded to employees and executive officers; half vest over 4 years, half upon milestone achievement under Roche License Agreement.
Roche deal includes $50M upfront payment and up to $620M in developmental, regulatory, and commercial milestones.
OpRegen cell therapy for ocular disorders (dry AMD with geographic atrophy) is subject of the exclusive worldwide license.
Tiered double-digit royalties on net sales of OpRegen, subject to intellectual property and competitive product offsets.
RSUs granted under 2021 Equity Incentive Plan; continued vesting requires continuous service.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.